Drug Type Proteolysis-targeting chimeras (PROTAC) |
Synonyms |
Target |
Mechanism BRD2 inhibitors(Bromodomain-containing protein 2 inhibitors), BRD3 inhibitors(Bromodomain-containing protein 3 inhibitors), BRD4 degraders(Bromodomain-containing protein 4 degraders) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization- |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC47H39ClN10O7S |
InChIKeyJMKRCXQLFWBWLX-DPHWTFSXSA-N |
CAS Registry- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | US | 21 Feb 2020 | |
Neoplasms | Preclinical | DE | 21 Feb 2020 |